SCHEMBL30129635

SCHEMBL30129635

COc1ncc(F)c(-c2cccc(O)c2)n1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 7/20 0.47
HSD17B2 P37059 7/20 0.47
FTO Q9C0B1 1/20 0.44
PIK3CG P48736 3/20 0.42
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
FYN P06241 4/20 0.39
BMPR1A P36894 1/20 0.39
TGFBR1 P36897 1/20 0.39
ACVRL1 P37023 1/20 0.39
ACVR1 Q04771 1/20 0.39
ADORA1 P30542 1/20 0.39
SYK P43405 1/20 0.38
ABL1 P00519 1/20 0.38
FLT3 P36888 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27632005 0.78 ADORA1 (0.62) HSD17B1HSD17B2PIK3CGADORA1ABL1
SCHEMBL30129595 0.77 RXFP1 (0.44) HSD17B1HSD17B2PIK3CGADORA1SYK
SCHEMBL29914724 0.77 FTO (0.66) HSD17B1HSD17B2FTOCYP1A2CYP3A4
SCHEMBL28430998 0.77 FTO (0.66) HSD17B1HSD17B2FTOCYP1A2CYP3A4
SCHEMBL29461710 0.74 HSD17B1 (0.56) HSD17B1HSD17B2CYP1A2CYP3A4CYP2C9
SCHEMBL29461811 0.72 HSD17B1 (0.58) HSD17B1HSD17B2CYP1A2CYP3A4CYP2C9
SCHEMBL30260606 0.72 HSD17B2 (0.49) HSD17B1HSD17B2FTOPIK3CGCYP1A2
SCHEMBL9160918 0.70 IDO1 (0.45) HSD17B1HSD17B2FYNBMPR1ATGFBR1
SCHEMBL9160925 0.69 HSD17B1 (0.45) HSD17B1HSD17B2CYP1A2CYP2C9CYP2C19
SCHEMBL28346658 0.69 FTO (0.39) FTOCYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-26 US disclosed
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 HSD17B1 2388/4885HSD17B2 2816/4885FTO 2943/4885
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 HSD17B1 2342/4885HSD17B2 2758/4885FTO 3141/4885
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 HSD17B1 2342/4885HSD17B2 2758/4885FTO 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.